Smartphone application-based pulmonary rehabilitation in COPD: a multicentre randomised controlled trial.

However, access to conventional face-to-face PR programmes is limited.

然而，传统面对面肺康复计划的可及性有限。

Methods

This multicentre, randomised controlled trialrecruited patients with COPD from 18 sites in Germany and Switzerland, aiming to evaluate the impact of 12 weeks of a mobile app (intervention group; IVG) on quality of life, measured by COPD Assessment Test (CAT), and exercise capacity, assessed by 1-minute-sit-to-stand-test (1MSTST), compared with a control group (CTG) receiving 'enhanced standard-of-care'.

这项多中心随机对照试验在德国和瑞士的18个地点招募了慢性阻塞性肺疾病（COPD）患者，旨在评估12周移动应用程序（干预组；IVG）对生活质量的影响，通过慢性阻塞性肺疾病评估测试（CAT）测量，并通过1分钟坐立测试（1MSTST）评估运动能力，与接受“增强标准护理”的对照组（CTG）进行比较。

Results

278 patients were included in the study with a median age of 65 years (IQR 60-70) and forced expiratory volume in 1 s 48% predicted (IQR 37-60).

研究共纳入了278名患者，中位年龄为65岁（四分位数间距60-70岁），第一秒用力呼气容积为48%预测值（四分位数间距37-60%）。

In the intention-to-treatanalysis at week 12, CAT improved from baseline by median -4 points versus -3 points in the IVG versus CTG groups, respectively (difference: 0 points (95% CI: -1, 2); p=0.7); 1MSTST improved by 1 vs 2 repetitions, respectively (difference: 1 repetition (95% CI: 0, 2); p=0.12)).

在第12周的意向治疗分析中，与基线相比，CAT评分在IVG组和CTG组分别改善了中位数-4分和-3分（差异：0分（95%置信区间：-1, 2）；p=0.7）；1MSTST分别增加了1次和2次重复（差异：1次重复（95%置信区间：0, 2）；p=0.12）。

In a subset of the IVG, with patients grouped by application adherence (≥3 days/week for≥75% of the weeks), adherent users (40.4%) improved 1MSTST versus non-adherent users by median 2 repetitions (95% CI: 1, 3]; p=0.006.

在IVG的一个子集中，根据应用依从性（每周≥3天，持续≥75%的周数）对患者进行分组，依从性良好的用户（40.4%）的1MSTST比依从性差的用户中位数增加了2次重复（95%置信区间：1, 3]；p=0.006。

Application use did not raise any safety concerns.

应用程序的使用没有引起任何安全问题。

Conclusions

Application-based PR improved outcomes in COPD compared with baseline, and adherent users improved exercise capacity more compared with non-adherent users.

与基线相比，基于应用程序的PR改善了COPD患者的预后，且依从性良好的用户比依从性差的用户在改善运动能力方面效果更显著。

Although not statistically significant compared with enhanced standard-of-care, this study may support the use of this application for COPD management and addresses the healthcare challenge of access to PR interventions.

尽管与增强的标准护理相比没有统计学意义，但本研究可能支持使用此应用程序进行慢性阻塞性肺疾病（COPD）管理，并解决了获取肺康复（PR）干预措施的医疗挑战。

trial_registration_number

DRKS 00024390.

DRKS 00024390。